Your session is about to expire
← Back to Search
Other
DC-806 for Plaque Psoriasis (Illuminate Trial)
Phase 2
Waitlist Available
Research Sponsored by DICE Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial is testing a new oral medication called DC-806. It targets people with moderate to severe plaque psoriasis. The study will check how well the medication works, its safety, and how the body processes it.
Who is the study for?
Adults aged 18-70 with moderate to severe plaque psoriasis, who have had it for at least 6 months and are candidates for phototherapy or systemic therapy. They must have a BMI of 18-40 kg/m2 and agree to use effective contraception. Exclusions include certain abnormal lab values, recent flares or infections, history of significant mental health issues, strong drug interactions, heart abnormalities, chronic infections like HIV/hepatitis/TB, cancer in the last 5 years (except some skin cancers), or no response to specific psoriasis treatments.
What is being tested?
The trial is testing DC-806's effectiveness and safety compared to a placebo over a period of 12 weeks. Participants will be randomly assigned to receive either multiple oral doses of DC-806 or a placebo in double-blind fashion (neither participants nor researchers know who receives which treatment). The study also looks into how the body processes the drug.
What are the potential side effects?
While not specified here, common side effects for new psoriasis medications can include symptoms like nausea, diarrhea, headache, fatigue and potential risks for infection due to immune system impact. Specific side effects related to DC-806 would be detailed based on previous research phases.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
5Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment Group 4: DC-806 Dose DExperimental Treatment1 Intervention
Group II: Treatment Group 3: DC-806 Dose CExperimental Treatment1 Intervention
Group III: Treatment Group 2: DC-806 Dose BExperimental Treatment1 Intervention
Group IV: Treatment Group 1: DC-806 Dose AExperimental Treatment1 Intervention
Group V: Treatment Group 5: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DC-806
2023
Completed Phase 2
~300
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Plaque Psoriasis include TNF-alpha inhibitors, IL-12/23 inhibitors, and small molecules targeting specific pathways. TNF-alpha inhibitors reduce inflammation by blocking the tumor necrosis factor-alpha, a cytokine involved in systemic inflammation.
IL-12/23 inhibitors target interleukins 12 and 23, which are crucial in the inflammatory process of psoriasis. Small molecules like DC-806, which are being studied, often inhibit specific enzymes or receptors involved in the pathogenesis of psoriasis, such as phosphodiesterase-4 (PDE4) inhibitors.
These treatments are important for patients as they help reduce the chronic inflammation and abnormal skin cell growth characteristic of Plaque Psoriasis, leading to improved skin appearance and reduced symptoms.
Investigation on the Mechanism of Qubi Formula in Treating Psoriasis Based on Network Pharmacology.Trim21 promotes inflammation in keratinocytes of psoriatic patients.The Psoriasis Therapeutic Potential of a Novel Short Laminin Peptide C16.
Investigation on the Mechanism of Qubi Formula in Treating Psoriasis Based on Network Pharmacology.Trim21 promotes inflammation in keratinocytes of psoriatic patients.The Psoriasis Therapeutic Potential of a Novel Short Laminin Peptide C16.
Find a Location
Who is running the clinical trial?
DICE Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
41 Total Patients Enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyLead Sponsor
7 Previous Clinical Trials
448 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,369 Previous Clinical Trials
421,165 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a history of severe psoriasis worsened by medication.My psoriasis has significantly worsened in the last 12 weeks.I haven't had cancer or similar diseases in the last 5 years, except for treated skin cancer without return.I am not taking strong or moderate drugs that affect liver enzymes.I am between 18 and 70 years old.I have been diagnosed with plaque psoriasis for at least 6 months.I have a history of chronic infections like HIV or hepatitis.I did not respond to treatments targeting IL-17 after 3 months.I have had active tuberculosis in the past.I am willing to use effective birth control during and for 30 days after the study.I have not had a serious infection or fever in the past 7 days.My blood tests show I have specific abnormal levels that may affect my study participation.My psoriasis covers more than 10% of my body and is moderate to severe.I am considered a candidate for light or systemic therapy.I am willing to stop my current psoriasis treatments before starting the study drug.I have had thoughts or actions of suicide recently or in the past 5 years.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment Group 3: DC-806 Dose C
- Group 2: Treatment Group 5: Placebo
- Group 3: Treatment Group 1: DC-806 Dose A
- Group 4: Treatment Group 2: DC-806 Dose B
- Group 5: Treatment Group 4: DC-806 Dose D
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Plaque Psoriasis Patient Testimony for trial: Trial Name: NCT05896527 — Phase 2
Share this study with friends
Copy Link
Messenger